Overview

A class action lawsuit has been filed against Semler Scientific, Inc. (“Semler Scientific” or the “Company”) and certain of the Company’s former and current senior executive officers alleging violations of the federal securities laws. Semler Scientific common stock trades on the Nasdaq Stock Market LLC (the “NASDAQ”) under the ticker symbol “SMLR”.

The Semler Scientific class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired publicly traded securities of Semler Scientific between March 10, 2021, and April 15, 2025, both dates inclusive, (the “Class Period”).

Semler Scientific is a healthcare technology company that develops and markets products and services designed to assist in the evaluation and treatment of chronic diseases. Its primary product, QuantaFlo, is a patented and FDA-cleared device that measures arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease (PAD).

In addition to its healthcare operations, Semler Scientific has also adopted bitcoin as its primary treasury reserve asset. The company uses cash flows from its healthcare business, along with proceeds from equity and debt financings, to accumulate bitcoin. While its healthcare technology solutions remain its core operational focus, these activities provide the financial foundation to support its bitcoin investment strategy.

The lawsuit alleges that Defendants, throughout the Class Period, issued materially false and misleading statements by failing to disclose adverse facts about Semler Scientific’s business that were known to them or recklessly disregarded. Specifically, Defendants did not disclose a material investigation by the United States Department of Justice into potential violations of the False Claims Act. Instead, they discussed possible violations and DOJ enforcement only in hypothetical terms, giving investors a misleading impression of the Company’s exposure. As a result, Defendants’ public statements regarding the Company’s business, operations, and compliance posture were materially false and misleading at all relevant times.

*          *          *

If you purchased or otherwise acquired publicly traded securities of Semler Scientific between March 10, 2021, and April 15, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Semler Scientific class action lawsuit is October 28, 2025